Exelixis Inc

EXEL Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of EXEL by members of U.S. Congress

Politician Type Traded
Donna E. Shalala House / D Sale $1,001 - $15,000 Jun. 04, 2019
Donna E. Shalala House / D Sale $1,001 - $15,000 Apr. 16, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Feb. 06, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Jan. 09, 2019
EXEL Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
EXEL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
EXEL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by EXEL's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $460,000 Apr 18, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Jan 21, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $450,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $450,000 Jan 19, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $330,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $320,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $300,000 Jul 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Apr 19, 2022 Issue: Health Issues
  • $280,000 Jan 19, 2022 Issue: HEALTH ISSUES
  • $230,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Apr 19, 2021 Issue: HEALTH ISSUES
  • $220,000 Jan 20, 2021 Issue: HEALTH ISSUES
  • $240,000 Oct 20, 2020 Issue: HEALTH ISSUES
  • $240,000 Jul 20, 2020 Issue: HEALTH ISSUES
  • $220,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: HEALTH ISSUES
  • $180,000 Oct 21, 2019 Issue: Health Issues
  • $320,000 Jul 22, 2019 Issue: Health Issues
  • $300,000 Apr 22, 2019 Issue: Health Issues
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jan 17, 2019 Issue: Health Issues
  • $60,000 Oct 09, 2018 Issue: Health Issues
  • $60,000 Jul 18, 2018 Issue: Health Issues
  • $50,000 Apr 19, 2018 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

Revenue Breakdown

EXEL Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
EXEL Income Statement
EXEL Balance Sheet
EXEL Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Heterocyclic adenosine receptor antagonists Apr. 01, 2025
  • Patent Title: Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use Feb. 18, 2025
  • Patent Title: Compounds for the treatment of kinase-dependent disorders Jan. 14, 2025
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Oct. 29, 2024
  • Patent Title: Anti-ror antibody constructs Sep. 10, 2024
  • Patent Title: Crystalline forms and salt forms of a kinase inhibitor Jun. 25, 2024
  • Patent Title: Liquid dosage forms to treat cancer Jun. 25, 2024
  • Patent Title: Method of treating cancer Apr. 30, 2024
  • Patent Title: Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use Sep. 19, 2023
  • Patent Title: Heterocyclic adenosine receptor antagonists Aug. 08, 2023
  • Patent Title: Compounds for the treatment of kinase-dependent disorders Jul. 25, 2023
  • Patent Title: Compounds for the treatment of kinase-dependent disorders Jun. 13, 2023
  • Patent Title: Method of treating cancer Mar. 28, 2023
  • Patent Title: Mek inhibitors and methods of their use Mar. 07, 2023
  • Patent Title: Cabozantinib dosage form and use in the treatment of cancer Jan. 31, 2023
  • Patent Title: Compounds for the treatment of kinase-dependent disorders Jan. 03, 2023
  • Patent Title: Method of treating cancer and bone cancer pain Nov. 22, 2022
  • Patent Title: Liquid dosage forms to treat cancer Nov. 22, 2022
  • Patent Title: Methods of using c-met modulators Sep. 06, 2022
  • Patent Title: Process for making compounds for use in the treatment of cancer Aug. 16, 2022
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Apr. 12, 2022
  • Patent Title: Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use Mar. 22, 2022
  • Patent Title: Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone Feb. 22, 2022
  • Patent Title: Combinations of cabozantinib and atezolizumab to treat cancer Dec. 14, 2021
  • Patent Title: Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate Oct. 12, 2021
  • Patent Title: C-met modulators and methods of use Sep. 21, 2021
  • Patent Title: Method of preparing fluorine-18 labeled cabozantinib and its analogs Sep. 21, 2021
  • Patent Title: C-met modulator pharmaceutical compositions Sep. 21, 2021
  • Patent Title: Method of treating cancer Sep. 14, 2021
  • Patent Title: Malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer Aug. 24, 2021
  • Patent Title: Malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- n′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer Aug. 17, 2021
  • Patent Title: Malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer Aug. 17, 2021
  • Patent Title: Drug combinations to treat multiple myeloma Jul. 20, 2021
  • Patent Title: Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use Dec. 01, 2020
  • Patent Title: Process for making compounds for use in the treatment of cancer Oct. 06, 2020
  • Patent Title: Methods of using c-met modulators Aug. 11, 2020
  • Patent Title: Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone Mar. 17, 2020
  • Patent Title: C-met modulator pharmaceutical compositions Feb. 04, 2020
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Jan. 28, 2020
  • Patent Title: Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use Dec. 10, 2019
  • Patent Title: Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies Jun. 25, 2019
  • Patent Title: Metabolites of n-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Apr. 30, 2019
  • Patent Title: Process for making compounds for use in the treatment of cancer Mar. 26, 2019
  • Patent Title: Method for treating osteoporosis Jan. 01, 2019
  • Patent Title: Dosing of cabozantinib formulations Dec. 25, 2018
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Nov. 13, 2018
  • Patent Title: Inhibitors of pi3k-delta and methods of their use and manufacture Aug. 21, 2018
  • Patent Title: C-met modulator pharmaceutical compositions Aug. 07, 2018
  • Patent Title: Rorγ modulators Jul. 31, 2018
  • Patent Title: C-met modulator pharmaceutical compositions Jul. 31, 2018
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

EXEL News

Recent insights relating to EXEL

CNBC Recommendations

Recent picks made for EXEL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in EXEL

EXEL Analyst Ratings

EXEL Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
EXEL Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $EXEL stock a Buy, Sell, or Hold?

  • What is the price target for $EXEL stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

EXEL Top Shareholders
Shareholder
Shares Held
EXEL Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $EXEL stock?

  • Who owns the most shares of $EXEL stock?

  • What funds own $EXEL stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

EXEL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view EXEL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top